Citations

Clear

3030 citation(s) found for "Susan, M".

Bim and soluble PD-L1 (sPD-L1) as predictive biomarkers of response to anti-PD-1 therapy in patients with melanoma and lung carcinoma.
Dronca, Roxana , Harrington, Susan M. , Kottschade, Lisa A. , Koo, Chi Wan , Block, Matthew S. , Nevala, Wendy K. , Mansfield, Aaron S. , Liu, Xin , Enninga, Elizabeth Ann L. , McWilliams, Robert R. , Markovic, Svetomir N. , Dong, Haidong

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 11534-11534

10.1200/jco.2017.35.15_suppl.11534 Get It

11534 Background: To date, there are no validated blood-based biomarkers of predicting response to PD-1 blockade. We previously reported that Bim is a downstream signaling molecule of the PD-1 pathway, and that measurement of Bim levels in circulating T-cells may predict and monitor responses to anti–PD-1 therapy in melanoma. We have identified the existence of sPD-L1 in cancer patients and showed that the sPD-L1 is biologically active and capable of triggering apoptosis in activated T-cells. Here we evaluated T cell Bim and sPD-L1 in the peripheral blood (PB) as biomarkers of response in a cohort of patients with metastatic melanoma and lung cancer undergoing anti-PD1 therapy. Methods: 60 pts treated with anti-PD-1 had PB collected at baseline and at radiographic tumor evaluation. Frequencies of Bim+ T cells and Bim median fluorescence intensity (MFI) were measured by flow cytometry in gated tumor-reactive CD11ahighPD1+ CD8+ T cells. We also measured levels of sPD-L1 at baseline and serially during treatment with sPD-L1 ELISA. Baseline Bim and sPD-L1 levels and percent change in Bim levels in patients (pts) who had a radiographic response (CR/PR) were compared to those who had progressive disease (PD) at 12 wks. Results: Similarly to previously reported preliminary data, pts with objective response (CR/PR, 15/60) after 4 cycles of anti-PD1 therapy had higher frequency of Bim T cells at baseline compared to pts with PD (16/60) (mean 43% vs. 30%, P = 0.0484). The frequencies of Bim+ T cells decreased significantly after the first 3 months of treatment in responders compared with progressors (mean -16% vs. + 40% P = 0.0111). High baseline sPD-L1 were associated with progression on anti-PD1 therapy (mean 2.8 ng/mL vs. 0.7 ng/mL, p = 0.07, n = 13) and the levels increased by the first tumor assessment in patients resistant to anti-PD-1. Conclusions: Measurements of Bim and sPD-L1 levels may help to select patients who are likely to benefit from anti-PD1 monotherapy versus combinatorial strategies, and provide a new non-invasive way to monitor response to anti-PD-1 blockade. A larger validation study is underway.
Cancer-associated macrophage-like cells as prognostic indicators of overall survival in a variety of solid malignancies.
Adams, Diane K. , Martin, Stuart S. , Chumsri, Saranya , Lapidus, Rena G. , Tang, Cha‐Mei , Alpaugh, R. Katherine , Adams, Daniel L. , Lin, Steven H. , Cristofanilli, Massimo , Bergan, Raymond C. , Marks, Jeffrey R. , Ho, Thai H. , Tsai, Susan

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 11503-11503

10.1200/jco.2017.35.15_suppl.11503 Get It

11503 Background: Cancer Associated Macrophage-Like cells (CAMLs) are a recently described circulating stromal cell subtype commonly found in the peripheral blood of patients in all stages of solid malignancies and in a variety of cancer subtypes. However, while their biological association to cancer is being studied, their clinical utilization as it relates to cancer prognosis has not been evaluated. Methods: A two year prospective study was undertaken to evaluate the relationship of CAMLs and overall survival (OS) in 6 solid tumor types. The single blind multi-institutional study consisted of 269 stage I-IV patients; breast (n = 57), esophageal (n = 21), prostate (n = 43), pancreatic (n = 59), lung (n = 54), and renal cell (n = 35), in treatment (n = 134) and untreated baseline (n = 135). 7.5mL of whole blood was filtered by CellSieve microfiltration assay and CAMLs enumerated, as previously described. Patients were grouped by CAML number ( < 6 or ≥6) and by size ( < 49 or ≥50 µm) to evaluate hazard ratios (HR) by censored univariate & multivariate analysis. Results: CAMLs were identified in 93% of samples, averaging 8.2 CAMLs/7.5mL blood sample, and found in all 6 cancers at baseline and during treatment. Average CAML number was associated with disease stage and CAML positivity was 4.4 & 80% (Stage I), 4.7 & 93% (Stage II), 9.3 & 98% (Stage 3), 12.1 & 97% (Stage IV). Univariate analysis of patients (n = 269) stratified by ≥6 CAMLs had reduced OS (HR = 1.8, 95%CI 1.1-2.9, p = 0.03). Further, CAML size also had reduced OS in patients with ≥50 µm CAMLs (HR = 2.7, 95%CI 1.8-4.0, p < 0.0001). Conclusions: Our data suggests that in solid malignancies, CAML number and size appear to clinically correlate with OS in early and late stage disease. Given these results relating CAMLs with OS, further analysis is warranted to determine if CAMLs can serve as a clinically-relevant blood-based marker.
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL).
Sposto, Richard , Rodriguez, Vilmarie , Bhojwani, Deepa , Shah, Nirali N , O'Brien, Maureen Megan , McNeer, Jennifer L. , Loh, Mignon L. , Rheingold, Susan R

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 10512-10512

10.1200/jco.2017.35.15_suppl.10512 Get It

10512 Background: Inotuzumab ozogamicin (InO), a CD22-targeting antibody linked to calicheamicin demonstrated exceptional activity in R/R ALL in adults. InO has been available to pediatric patients with R/R ALL via a compassionate access program. Methods: Participating international pediatric oncology centers received IRB approval to submit retrospective demographic, outcome and toxicity data on pediatric patients who received at least one dose of InO. Results: Thirty-four patients, age 2.3-21.4 yrs (median 11.7) received 1-4 cycles (3 weekly doses) of InO. Patients were heavily pretreated in 1st-5threlapse; 28 were refractory to their preceding regimen. Thirteen patients had prior hematopoietic stem cell transplant (HSCT), 27 received prior CD19 and 8 prior CD22-directed therapy. Pre-InO disease was M3 ( > 25% blasts) in 26 patients, M2 (5-25%) in 3, and MRD only in 5 (1 with extramedullary disease). Of 29 patients with M2/M3 disease at baseline, 18 (62%) achieved a complete remission (CR), 13 of whom were MRD negative. Post-InO, 15 patients proceeded to HSCT and 5 to CAR T-cell therapy. Alterations in CD22 expression at subsequent relapse were noted in two patients with available blasts samples. No deaths were attributed to InO during therapy. The incidence of grade 3/4 infections was 38% and were of the expected types. Grade 1-4 hepatic toxicity was noted in 11/34 (32%) patients, primarily asymptomatic elevations in transaminases/bilirubin. There was no sinusoidal obstruction syndrome (SOS) during InO therapy but 8/15 patients who received HSCT post-InO developed SOS. One patient died from SOS, but the others recovered. The incidence of SOS was higher in patients who had undergone prior HSCT (6/8) versus no prior HSCT (2/7). SIRS (1), neurotoxicity (2) and hemorrhage (3) were infrequent. Three patients had musculoskeletal pain associated with edema. Conclusions: Single agent InO had a CR rate of 62% in heavily pretreated pediatric patients. Toxicities were similar to adults with hepatic and infectious toxicity being the most common. Overall InO was well tolerated, but the incidence of SOS was high in patients who underwent HSCT post-InO, particularly in those who had undergone a prior HSCT.
Effect of cabozantinib on bone turnover markers (BTM) and bone metastases (BM) in radioiodine refractory (RAIR)-differentiated thyroid cancer (DTC).
Knopp, Michael V. , Martin, Peter R. , Geyer, Susan, Souza, Jonas A. de, Wirth, Lori J. , Menefee, Michael E., Shah, Manisha H. , Konda, Bhavana , Cabanillas, Maria E. , Liu, Stephen V.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: e17580-e17580

10.1200/jco.2017.35.15_suppl.e17580 Get It

e17580 Background: Cabozantinib is a small molecule multiple-receptor tyrosine kinase inhibitor that primarily targets MET and vascular endothelial growth factor receptor 2 (VEGFR2). We evaluated the effect of cabozantinib on BTM in RAIR DTC. We also assessed the response of BM to cabozantinib using 18F Sodium Fluoride (NaF) PET and radionuclide bone scans. Methods: This prospective analysis was performed as part of a multicenter International Thyroid Oncology Group phase II study of cabozantinibin patients with RAIR DTC who progressed on prior VEGFR-targeted therapy (NCT01811212). BTM [serum C-telopeptide (CTx), osteocalcin, N-telopeptide (NTx), procollagen type 1 (Pc1) and urinary NTx] and NaF PET or Tc-MDP scans were done at baseline and after 8 weeks of therapy. A paired t-test was used between baseline and week 8 BTM. Results: Primary study results were presented elsewhere (Shah, et al. 2015, International Thyroid Congress) showing a response rate of 36% with cabozantinib. Of 25 patients (pts) enrolled, 21 had BM, 10 of whom were on bone-modifying agents (BMA) prior to week 8. Only 2 pts had elevated BTM at baseline. In all pts who had paired BTM, there was a statistically significant decline in all BTM except NTx by week 8 (table). Pts not on BMA also had a significant decline in CTx (p 0.0003), urine NTx (p 0.0300), and Pc1 (p 0.0030) compared to baseline. 19 pts were evaluable for overall response and there was no correlation between BTM and response rate. 6/21 patients underwent paired NaF PET scans and 4/6 had minor reduction in lesion uptake at 8 weeks. Conclusions: Interestingly, most of our patients had normal baseline BTM despite BM. Cabozantinib was associated with a strikingly significant reduction in all BTM (even when BTM were within normal limits at baseline) except NTx by week 8. Minor decreases in bone lesion uptake was noted on NaF PET in 4/6 evaluable patients. Clinical trial information: NCT01811212. [Table: see text]
Impact of timing of administration of bone supportive therapy on pain palliation from radium-223.
Yap, Kelly Khai Li, Wong, William W. , Ji, Lingyun , Groshen, Susan , Pinski, Jacek, Dorff, Tanya B. , Quinn, David I , Bryce, Alan H.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 5023-5023

10.1200/jco.2017.35.15_suppl.5023 Get It

5023 Background: Skeletal-related events (SREs) drive morbidity in patients with metastatic castration-resistant prostate cancer (mCRPC). In the ALSYMPCA study, Radium-223 (Ra223) was found to palliate pain in addition to prolonging survival and reducing SREs. Earlier onset of pain relief was noted when zoledronic acid (ZA) was administered within 24-48 hours of samarium; we evaluated whether the timing of bone supportive therapy (BST) affected pain palliation fromRa223. Methods: We identified patients who received Ra223 at University of Southern California or Mayo Clinic Arizona. Data extracted: Ra223 administration dates, pain scores, pain medications, ZA or denosumab administration dates, alkaline phosphatase (ALP) levels, prostate specific antigen (PSA) levels, and concurrent prostate cancer therapy. Patients were evaluable for pain response if they had at least 2 pain scores documented before and after Ra223 with pain medication use data. Pain response was defined as > 2 point decrease in pain on a 10 point scale; flare was defined as > 2 point increase followed by return to baseline or lower. Results: Of 65 patients, 20 had baseline pain score > 0 and 34 were evaluable. Median #doses Ra223 was 5 (range 2-6). 18 patients received concurrent abiraterone (abi) or enzalutamide (enza), 16 did not. Pain response occurred in 6/6 (100%) patients who received BST within 1 month prior to first Ra223 dose and 4/8 (50%) patients who did not receive BST. Pain flare occurred in 6/21 patients (29%) without BST and 2/13 (15%) with BST. 6/10 (60%) patients with pain response had ALP decline but there was no consistent pattern of ALP changes in patients with flare. 8/8 patients with pain response had no PSA decline (6 increased, 2 stable). 6/12 (50%) and 2/22 (9%) patients on abi/enza had pain response and flare respectively, and 4/8 (50%) and 6/19 (32%) patients without concurrent abi/enza had response/flare. Conclusions: BST within 1 month prior to first Ra223 may be associated with increased likelihood of pain palliation and may prevent pain flare. PSA/ALP changes do not predict pain response. Concurrent use of abi/enza does not increase the likelihood of pain response and may decrease the likelihood of flare.
Guidelines for management of urgent symptoms in cholangiocarcinoma (CC) patients (pts) with biliary stents or catheters using the modified RAND/UCLA Delphi process.
Iyer, Renuka , Acquisto, Susan, Choti, Michael A., Hong, Theodore S. , Kis, Béla , Mead, Peter A., Roberts, Lewis R. , Parikh, Neehar D. , Siegel, Richard S., Whisenant, Jonathan, Cherepanov, Dasha , Broder, Michael S. , Roberts, Lewis R , Parikh, Neehar D , Bridgewater, John , Roberts, Rebecca, Sicklick, Jason Keith , Valle, Juan W.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: e15641-e15641

10.1200/jco.2017.35.15_suppl.e15641 Get It

e15641 Background: CC pts with biliary stents or catheters are prone to have obstruction/infection and studies show 20-40% present with fever/or jaundice requiring urgent treatment for which there is no uniform guideline. We aimed to develop an expert panel consensus on this topic using the modified RAND/UCLA Delphi process to rate treatment appropriateness. Methods: We recruited 13 physician experts from relevant specialty, geography, and practice settings. Patient scenarios were developed and panelists rated the therapies before and after a face-to-face discussion. The appropriateness of various therapies was rated on a 1-9 scale and classified as appropriate, inappropriate, or uncertain. Scenarios with > 2 ratings of 1-3 (inappropriate) and > 2 ratings of 7-9 (appropriate) were considered to have disagreement and were not assigned an appropriateness rating. Results: Panelists were from all US regions (92%) and the UK (8%); had practiced for a mean 16.5 years (4-33 years). Panelists rated 480 scenarios before the meeting, but re-rated only 288 clinical scenarios as they felt that ongoing treatment with chemotherapy did not influence decision-making. Disagreement decreased from 37.5% before the meeting to 10.4% after. Consensus statements are summarized in the table below. Conclusions: The Delphi process produced consensus guidelines to fill an unmet need in urgent management of ascending cholangitis in pts with CC. (Support: The Cholangiocarcinoma Foundation). [Table: see text]
Phase II study of alisertib, irinotecan, and temozolomide in children with relapsed and refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.
DuBois, Steven G. , Marachelian, Araz , Fox, Elizabeth , Kudgus, Rachel A. , Groshen, Susan , Malvar, Jemily , Wagner, Lars M. , Hawkins, Randall A., Lai, Hollie , Boucher, Najee, Czarnecki, Scarlett, Mossé, Yaël P. , Reid, Joel M. , Bagatell, Rochelle , Maris, John M. , Courtier, Jesse , Goodarzian, Fariba , Shimada, Hiroyuki , Tsao-Wei, Denice D , Matthay, Katherine K.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 10556-10556

10.1200/jco.2016.34.15_suppl.10556 Get It

Vitamin D and aromatase inhibitor-induced arthralgia: Analysis of Canadian cancer trial group MA.27 data.
Chapman, Judy Anne, Agarwal, Sandeep K. , Welschhans, Robert L., Bongartz, Tim, Shepherd, Lois E. , Bartlett, John M.S. , Rimawi, Mothaffar F. , Osborne, C. Kent , Goss, Paul E. , Rimawi, Mothaffar , Niravath, Polly Ann , Chen, Bingshu E. , Chapman, Judy‐Anne W., Kalari, Krishna R. , Pritchard, Kathleen I. , Gelmon, Karen A. , Hilsenbeck, Susan Galloway , Ingle, James N.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 10020-10020

10.1200/jco.2016.34.15_suppl.10020 Get It

Association of vitamin D insufficiency with inferior prognosis in follicular lymphoma.
Tracy, Sean , Ansell, Stephen M. , Nowakowski, Grzegorz S. , Thompson, Carrie A. , Inwards, David J. , Johnston, Patrick B. , Micallef, Ivana N. , Allmer, Cristine, Macon, William R. , Maurer, Matthew J. , Witzig, Thomas E. , Drake, Matthew T. , Weiner, George J. , Slager, Susan L. , Habermann, Thomas M. , Link, Brian K. , Cerhan, James R.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e19067-e19067

10.1200/jco.2016.34.15_suppl.e19067 Get It